To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early

This study has been terminated.
(Gm test became routinely available. We could not compare the two arms anymore.)
Sponsor:
Collaborator:
National University Hospital, Singapore
Information provided by:
Singapore General Hospital
ClinicalTrials.gov Identifier:
NCT00361517
First received: August 6, 2006
Last updated: June 23, 2009
Last verified: June 2009
  Purpose

Chemotherapy lowers the white blood cell count or weakens the immune system for a long time. This puts the patients at a high risk of getting a serious fungal infection of the internal organs or blood. One of these infections is caused by a mold called Aspergillus and can be life threatening. Usually doctors give preventive antifungal therapy to try to lower the risk of this infection. Despite this, patients are still at risk of getting fungal infection. This study is thus designed to test Galactomannan - a component of cell wall of Aspergillus and hence detect and treat fungal infection early.


Condition Intervention Phase
Aspergillosis
Behavioral: Galactomannan antigen monitoring, Aspergillus PCR
Other: blood draws
Other: blood draws for GM monitoring
Drug: Amphotericin-B deoxycholate
Other: blood test
Other: Blood test
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Using Serum Galactomannan Levels in a Prospective, Randomised, Non-Blinded Trial to Guide Early Anti-Fungal Therapy in Haematology Patients at Risk of Invasive Aspergillosis.

Resource links provided by NLM:


Further study details as provided by Singapore General Hospital:

Primary Outcome Measures:
  • Development of proven or probable invasive fungal infection, fungal related mortality and overall survival in an intention to treat basis. [ Time Frame: During neutropenia, or, in HSCT patients, while under immunosuppressive therapy ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Duration of antifungal therapy and toxicity associated with antifungal therapy. [ Time Frame: while patient is on follow-up. ] [ Designated as safety issue: Yes ]

Enrollment: 47
Study Start Date: June 2006
Estimated Study Completion Date: June 2009
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GM test
Twice weekly blood draws from the patients in this arm for serial GM monitoring. They will be given standard antifungal prophylaxis but no antifungal therapy unless two consecutive GM readings are positive.
Behavioral: Galactomannan antigen monitoring, Aspergillus PCR
There will be blood draws twice weekly for monitoring GM antigen and once a week for Aspergillus PCR.
Other: blood draws
Blood is drawn for monitoring of Galactomannan antigen in the blood
Other: blood draws for GM monitoring
blood samples will be taken twice weekly for monitoring of GM antigen levels in the blood and once a week for Aspergillus PCR.
Drug: Amphotericin-B deoxycholate
1-1.5mg/kg, i.v, once a day
Other Name: Fungizone, Abelcet, AmBisome, Fungisome, Amphocil,
Other: blood test
Blood will be tested twice a week for the presence of Galactomannan.
Other: Blood test
Blood will be drawn twice a week and it will be tested for the presence of GM(a component of the cell wall of the mold Aspergillus which is released during growth)
No Intervention: no GM monitoring
in this arm the patients will not have any GM monitoring and they will be given standard antifungal prophylaxis and treatment according to the published guidelines.

Detailed Description:

The diagnosis of invasive Aspergillosis (IA) remains a challenge in the febrile neutropenic and the hematopoietic stem cell transplant (HSCT) recipients. Recent studies have shown that early diagnosis of IA is possible in this group of high-risk patients. Serial screening of circulating Galactomannan (GM), an epitopic determinant of several antigens secreted by the Aspergillus early in its growth, has been shown to be sensitive and specific in the diagnosis of IA. This test may help us to detect IA early, thereby permitting a pre-emptive strategy to be initiated in high-risk patients. In a prospective, randomized, non-blinded study, we seek to compare the outcome of a novel GM-guided anti-fungal strategy against the conventional empirical antifungal therapy. Patients randomized to the conventional arm will not undergo serial GM monitoring, but will receive standard anti-fungal prophylaxis and standard empirical antifungal therapy in accordance with published guidelines. Patients randomized to the GM arm will receive standard anti-fungal prophylaxis but will not receive empiric anti-fungal therapy unless 2 GM readings are positive. The study aims to determine if such a strategy permits targeted, pre-emptive therapy in those at greatest risk, and spare febrile patients without evidence of fungal infection other than prolonged fever from unnecessary and potentially toxic therapy. It also aims to determine if GM guided pre-emptive antifungal therapy using Amphotericin-B deoxycholate prevents the development of proven or probable invasive aspergillosis (IA). The study will also prospectively evaluate (in a blinded fashion) the use of realtime polymerase chain reaction (RT PCR) assay in the same cohort of patients receiving GM serial monitoring, and investigate its role in the diagnosis and treatment monitoring of invasive Aspergillosis.

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with newly diagnosed acute leukemia or high risk myelodysplastic syndrome (MDS) receiving induction chemotherapy with expected duration of neutropenia (absolute neutrophil count of < 500/mL) of at least 10 days
  2. Patients with relapsed acute leukemia or MDS receiving salvage chemotherapy with expected duration of neutropenia (absolute neutrophil count of < 500/mL) of at least 10 days
  3. Patients with severe aplastic anemia (SAA) receiving chemotherapy or immunosuppressive therapy using antithymocyte globulin
  4. Patients receiving allogeneic/autologous hematopoeitic stem cell transplant (HSCT) using myeloablative conditioning regimens
  5. Patients are at least 12 years of age, with Karnofsky score of 70%.?
  6. Patients on consolidation chemo regimens like HIDAC and HyperCVAD type B with expected duration of neutropenia (ANC < 500/ml) of at least 10 days

Exclusion Criteria:

  1. Patients who are human immunodeficiency virus (HIV) infected
  2. Patients with uncontrolled bacteremia or active pulmonary infection at the time of randomisation
  3. Patients with pre-existing proven and probable invasive fungal infections, according to the definitions of the invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Disease [10].
  4. Patients receiving concomitant piperacillin/tazobactam or co-amoxyclavulinic acid
  5. Patients on palliative chemotherapy
  6. Patients with history of allergy to triazoles
  7. Patients with prior history of anaphylactic reaction to conventional amphotericin B
  8. Patients with serum levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, or bilirubin more than 5 times the upper limit of normal or renal impairment with calculated creatinine clearance < 30ml/min
  9. Patients with expected life-expectancy < 72 hours
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00361517

Locations
Singapore
Singapore General Hospital
Singapore, Singapore, 169608
Sponsors and Collaborators
Singapore General Hospital
National University Hospital, Singapore
Investigators
Principal Investigator: Ban H Tan, Dr Singapore General Hospital
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr Tan Ban Hock, Singapore General Hospital
ClinicalTrials.gov Identifier: NCT00361517     History of Changes
Other Study ID Numbers: NMRC/0984/2005, IRB #291/2005
Study First Received: August 6, 2006
Last Updated: June 23, 2009
Health Authority: Singapore: Health Sciences Authority

Keywords provided by Singapore General Hospital:
GM monitoring
Immunocompromised
hematological disorder
Allogenic HSCT recipients
Aspergillus PCR assay

Additional relevant MeSH terms:
Aspergillosis
Hyalohyphomycosis
Dermatomycoses
Skin Diseases, Infectious
Infection
Mycoses
Skin Diseases
Amphotericin B
Amphotericin B, deoxycholate drug combination
Deoxycholic Acid
Amebicides
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Bacterial Agents
Antifungal Agents
Cholagogues and Choleretics
Gastrointestinal Agents

ClinicalTrials.gov processed this record on September 18, 2014